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Background
The ventricular ectopic QRS interval (VEQSI) has been shown to identify structural heart disease and predict mortality. In arrhythmogenic right ventricular cardiomyopathy (ARVC) early diagnosis is difficult with current methods and lifethreatening arrhythmias are common and difficult to predict.
Objectives
To assess the utility of ventricular ectopic indices including VEQSI in ARVC diagnosis.
Methods
We studied 70 patients with ARVC; 30 with definite disease (47±12 years; 60% male); 40 with incomplete disease expression (44±18 years; 44% male); 116 healthy controls (40±15 years; 56% male); and 26 patients with normal heart right ventricular outflow tract (RVOT) ectopy (46±17 years; 27% male). The duration of the broadest ventricular ectopic beat during 12-lead Holter monitoring was recorded as VEQSI max.
Results
VEQSI max was associated with age and gender, not conducted QRS duration.
Adjusted VEQSI max was greater in ARVC patients than control groups. In healthy males (44.5 years) estimated VEQSI max was 163ms (95%CI 159ms-167ms); in definite ARVC 212ms (95%CI 206ms-217ms); in incompletely expressed ARVC 204ms (95%CI 199ms-210ms); and in normal heart RVOT ectopy 171ms (95%CI 165ms-178ms). VEQSI max >180ms had 98% sensitivity 
Holter monitoring
Holter monitoring was performed for 24hours. Fragmentation measurements were made on a simultaneous 12-derivation ECG segment (10mm/mV, 25mm/s). VEB fragmentation was defined as >2 notches in the R' or S waves and/or 2 notches separated by >40ms. (10) The maximum number of fragmented leads was fragmentation max.
Inter-observer and intra-observer variability were measured using a subset of 22
Holter recordings analysed blindly by three different observers and on two occasions by one observer. Inter-observer variability intraclass correlation coefficients (ICC) were 0.93 for VEQSI max, 0.90 for VEB morphologies and 0.90
for VEB fragmentation max. Intra-observer variability ICC were 0.97 for VEQSI max, 0.99 for VEB morphologies and 0.95 for VEB fragmentation max.
Statistical analysis
Statistical tests were performed using STATA (StataCorp. Associations with other variables were expressed in terms of proportional odds for those in groups >k versus those in groups ≤k, where k is the level of the response variable defined above.
Receiver operating characteristic (ROC) curve analysis was used to examine the extent to which VEB indices can be used as markers of disease and establish diagnostic ranges. ARVC patients were compared with normal controls and RVOT ectopy patients. Accuracy was measured by area under the curve (AUC) and the corresponding results were compared. Thresholds for optimum sensitivity and specificity of each VEB index were derived, with results adjusted for age and gender.
Results
Holter characteristics
VEB were present in the majority of subjects (table 1) . In normal controls the commonest VEB morphology was RBBB superior axis suggesting an LV origin.
In ARVC the commonest VEB morphology was LBBB superior axis and in RVOT ectopy the commonest VEB morphology was LBBB inferior axis, suggesting right ventricular (RV) origins.
VT occurred in 30% definite ARVC, 15% incompletely expressed ARVC and 8%
RVOT ectopy patients. In definite ARVC the commonest VT morphologies were LBBB inferior and LBBB superior axis (44% patients with VT). In incompletely expressed ARVC the commonest VT morphology was LBBB superior axis (67% patients with VT). In RVOT ectopy all VT was LBBB inferior axis.
VEQSI max
VEQSI max was longer in definite and incompletely expressed ARVC patients than normal controls and RVOT ectopy patients (209±18ms, 200±12ms, 159±16ms and 165±14ms respectively; table 1; figure 2 ; raw data).
VEQSI max was associated with age and gender, not conducted QRS duration (table 2) . Adjusted VEQSI max remained greater in ARVC patients than control groups. In healthy males (average age 44.5 years) estimated VEQSI max was 163ms (95%CI 159ms-167ms); in definite ARVC 212ms (95%CI 206ms-217ms); in incompletely expressed ARVC 204ms (95%CI 199ms-210ms); and in RVOT ectopy 171ms (95%CI 165ms-178ms; supplementary table 2) .
VEB morphologies
There were more VEB morphologies in definite and incompletely expressed ARVC patients than normal controls and RVOT ectopy patients (5±4, 3±4, 1±1
and 2±1 respectively; table 1; raw data).
The number of VEB morphologies was associated with age and gender, not conducted QRS duration (table 2) . Adjusted VEB morphologies remained greater in ARVC patients than control groups. In incomplete ARVC the odds of ≥4 (vs <4)
VEB morphologies was 11.1 times greater than in normal controls and 2.6 times greater than in RVOT ectopy patients.
VEB fragmentation max
VEB fragmentation max was greater in definite and incompletely expressed ARVC patients than normal controls and RVOT ectopy patients (7±3, 3±4, 1±3
and 2±3 respectively; VEQSI max had 98% sensitivity and specificity for ARVC diagnosis (table 3) .
Comparison with Task Force criteria
VEQSI max >180ms identified 100% definite ARVC patients whereas major Task Force criteria for arrhythmias were met in 13-23% and minor criteria in 53-73% patients (supplementary table 4). VEQSI max >180ms identified 88%
incompletely expressed ARVC patients whereas major Task Force criteria for arrhythmias were met in 10% and minor criteria in 38-45% patients. VEQSI max excluded 85% of RVOT ectopy patients whereas minor ARVC Task Force criteria for arrhythmias were met in 58% patients. 
Prediction of events
VEQSI max and RV structural changes
In patients with normal RV size, VEQSI max was longer in those with definite and incompletely expressed ARVC compared with normal controls and RVOT ectopy patients (20215ms, 20012ms, 15916ms and 16514ms respectively). In RVOT origin VEB, VEQSI was longer in patients with definite and incompletely expressed ARVC compared with normal controls and RVOT ectopy patients (LBBB inferior axis VEB 18425ms, 19118ms, 15915ms and 16114ms respectively; figure 3 ).
Antiarrhythmic drugs
Nine ARVC patients received sotalol therapy which can influence conduction.
Following exclusion of these patients, VEQSI max remained longer in definite and incompletely expressed ARVC patients compared with normal controls and RVOT ectopy patients (206±18ms, 200±12ms, 161±15ms and 165±14ms respectively).
Discussion
VEB indices: VEQSI max, number of VEB morphologies and VEB fragmentation max distinguished patients with definite and incompletely expressed ARVC from normal controls and patients with normal heart RVOT ectopy. VEQSI max was the strongest index. VEQSI max >180ms had high sensitivity and specificity for the identification of ARVC, making it a potentially useful diagnostic test. Moreover VEQSI max >180ms increased the diagnostic yield in ARVC patients compared with Task Force criteria for arrhythmias.
Diagnosis of incompletely expressed ARVC
There is no gold standard investigation for ARVC; diagnosis relies on meeting VEQSI max was measured from the earliest VEB onset to the latest termination across all ECG leads whereas in previous studies QRS measurements were made for each individual lead. In addition, digital recording with high magnification measurement of an isolated VEB allows more accurate determination of VEB onset and termination than during VT on paper ECGs where low magnification measurements are more challenging and VEB onset and termination may be obscured by successive beats. 
Study Limitations
ARVC is a rare disease and the sample size is relatively small. In rare diseases sensitivity and specificity tests result in high values and ROC curve analysis has lower accuracy. The interpretation of results should be considered in this context.
Prospective validation of these phenotyping parameters was not possible which represents a major study limitation. Tables   Table 1 Data from 
